Brokerages Set Laboratory Co. of America Holdings (NYSE:LH) Price Target at $314.52

Shares of Laboratory Co. of America Holdings (NYSE:LH) have been given a consensus rating of “Buy” by the fifteen analysts that are presently covering the firm, Marketbeat reports. Thirteen research analysts have rated the stock with a buy recommendation. The average 12-month target price among analysts that have issued a report on the stock in the last year is $314.52.

Several equities analysts recently commented on the company. Mizuho upped their target price on Laboratory Co. of America from $318.00 to $332.00 and gave the company a “buy” rating in a research note on Thursday, August 19th. Deutsche Bank Aktiengesellschaft upped their target price on Laboratory Co. of America from $297.00 to $330.00 and gave the company a “buy” rating in a research note on Friday, July 30th. Credit Suisse Group upped their price target on Laboratory Co. of America from $295.00 to $336.00 and gave the stock an “outperform” rating in a research note on Friday, August 20th. Robert W. Baird set a $276.78 price target on Laboratory Co. of America and gave the stock a “buy” rating in a research note on Wednesday, July 21st. Finally, Zacks Investment Research upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $290.00 price target for the company in a research note on Wednesday, June 30th.

Laboratory Co. of America stock traded down $0.66 during trading on Tuesday, hitting $296.80. The company’s stock had a trading volume of 528,467 shares, compared to its average volume of 675,469. The stock has a market capitalization of $28.61 billion, a price-to-earnings ratio of 10.13, a P/E/G ratio of 1.21 and a beta of 1.04. The stock’s fifty day moving average is $294.79 and its 200 day moving average is $272.36. Laboratory Co. of America has a 1-year low of $176.49 and a 1-year high of $309.60. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.98 and a current ratio of 2.13.

Laboratory Co. of America (NYSE:LH) last released its earnings results on Wednesday, July 28th. The medical research company reported $6.13 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $5.64 by $0.49. The firm had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.59 billion. Laboratory Co. of America had a return on equity of 35.18% and a net margin of 17.57%. On average, research analysts anticipate that Laboratory Co. of America will post 23.55 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of LH. Kayne Anderson Rudnick Investment Management LLC boosted its position in shares of Laboratory Co. of America by 1,250.0% in the first quarter. Kayne Anderson Rudnick Investment Management LLC now owns 108 shares of the medical research company’s stock worth $28,000 after buying an additional 100 shares during the period. Liberty Wealth Management LLC boosted its holdings in Laboratory Co. of America by 27,486.7% in the second quarter. Liberty Wealth Management LLC now owns 8,276 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 8,246 shares during the last quarter. Eagle Bay Advisors LLC purchased a new position in Laboratory Co. of America in the second quarter valued at about $31,000. Grant Street Asset Management Inc. boosted its holdings in Laboratory Co. of America by 101.3% in the first quarter. Grant Street Asset Management Inc. now owns 157 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 79 shares during the last quarter. Finally, Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Laboratory Co. of America by 22.3% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 219 shares of the medical research company’s stock valued at $56,000 after purchasing an additional 40 shares during the last quarter. 88.29% of the stock is owned by institutional investors.

Laboratory Co. of America Company Profile

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions.

See Also: What are the Benefits of Index Funds?

Analyst Recommendations for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.